首页> 外文学位 >Mechanisms of CD4+ T cell tolerance in mixed allogeneic bone marrow chimeras prepared with CD40L blockade.
【24h】

Mechanisms of CD4+ T cell tolerance in mixed allogeneic bone marrow chimeras prepared with CD40L blockade.

机译:CD40L阻断剂制备的混合同种异体骨髓嵌合体中CD4 + T细胞耐受的机制。

获取原文
获取原文并翻译 | 示例

摘要

Tolerance regimens using bone marrow transplantation (BMT) permit permanent donor allo- or xenograft acceptance without compromising the immune system's competence to protect the host from disease, but the use of BMT for tolerance induction in the clinic has not been realized due to the toxicity of the conditioning regimens. Recently, progress has been made in animal models to develop non-myeloablative protocols for inducing mixed chimerism that utilize costimulatory blocking reagents that obviate the need for extensive host pre-treatment. High levels of multilineage mixed hematopoietic chimerism and systemic T cell tolerance can be achieved in mice through the use of anti-CD40L and costimulatory blockade (CTLA4Ig) alone or with recipient CD8 depletion and allogeneic bone marrow transplantation. While the establishment of central deletional tolerance serves as the primary means for the maintenance of donor-specific tolerance, the mechanisms by which costimulatory blockade facilitate the engraftment of allogeneic hematopoietic cells and the rapid tolerization of peripheral CD4+ T cells have not been defined in this protocol.; In various other experimental models using costimulatory blockade, anergy, immune deviation, suppression, and apoptosis have all been implicated as playing a role in graft prolongation. Analysis of chimeras that received BMT with anti-CD40L with CD8 depletion demonstrated the rapid development of specific tolerance (within 1 week post-BMT) and did not require a signal to the T cell through CD40L, suggesting that anti-CD40L is needed only to simply block CD40/CD40L interactions in order to induce CD4 cell tolerance. Furthermore, whereas evidence for the involvement of regulation, linked suppression, or cytokine deviation could not be demonstrated, anergy and the early deletion of allo-specific CD4+ T cells was observed, suggesting a critical role for these mechanisms in the induction of tolerance. Additionally, it appears that CTLA-4 may provide an important negative signal to peripheral CD4+ T cells within the first two days post-BMT. Together, these data are consistent with a hypothesis whereby blockade of T cell-APC costimulation through the CD40/CD40L pathway prevents the full activation of donor-reactive CD4 + T cells, potentially through an early CTLA-4-mediated negative signal followed by anergy and apoptosis through passive cell death pathways. These data also confirm that while the mechanisms involved in CD4+ T cell tolerance in this model are similar in some respects to other models of costimulatory blockade, the powerful tolerance achieved with a combination of anti-CD40L and BMT involves mechanisms that are unique to this combination.
机译:使用骨髓移植(BMT)的耐受方案允许永久性供体同种或异种移植,而不会损害免疫系统保护宿主免受疾病侵害的能力,但是由于BMT的毒性,尚未在临床上将BMT用于耐受诱导调理方案。最近,在动物模型方面已经取得进展,以开发用于诱导混合嵌合体的非清髓性方案,该方案利用了共刺激性封闭剂,从而无需进行广泛的宿主预处理。通过单独使用抗CD40L和共刺激阻断剂(CTLA4Ig)或与受体CD8耗竭和同种异体骨髓移植,可以在小鼠中实现高水平的多谱系混合造血嵌合和系统性T细胞耐受性。建立中央缺失耐受性是维持供体特异性耐受性的主要手段,而协同刺激阻断机制促进异基因造血细胞的植入和外周CD4 + T的快速耐受尚未在此协议中定义单元。在使用共刺激阻断的其他各种实验模型中,无反应性,免疫偏差,抑制和凋亡均与移植物延长有关。对接受抗CD40L和CD8耗竭的BMT的嵌合体进行的分析表明,特异性耐受快速发展(在BMT后1周内),不需要通过CD40L向T细胞发出信号,这表明抗CD40L仅需要只需阻断CD40 / CD40L相互作用即可诱导CD4细胞耐受。此外,虽然无法证明存在调节,连锁抑制或细胞因子偏离的证据,但观察到同种异体特异性CD4 + T细胞无能为力和早期缺失,提示这些细胞具有重要作用。诱导耐受的机制。此外,似乎CTLA-4可能在BMT后的前两天内向外周CD4 + T细胞提供重要的负信号。总之,这些数据与一个假设相符,即通过CD40 / CD40L途径阻断T细胞-APC共刺激可阻止供体反应性CD4 + T细胞的完全活化,这可能是通过早期的CTLA-4进行的。介导的负信号,然后通过被动细胞死亡途径导致无能和凋亡。这些数据还证实,虽然该模型中CD4 + T细胞耐受性的机制在某些方面与其他模型的共刺激阻滞相似,但抗CD40L和BMT的组合产生了强大的耐受性涉及此组合特有的机制。

著录项

  • 作者

    Kurtz, Josef Michael.;

  • 作者单位

    Harvard University.;

  • 授予单位 Harvard University.;
  • 学科 Health Sciences Immunology.
  • 学位 Ph.D.
  • 年度 2002
  • 页码 186 p.
  • 总页数 186
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 预防医学、卫生学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号